50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
The 3-Stock Retirement Blueprint (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Labour conference starts with focus on 'immoral' tax cuts
The 3-Stock Retirement Blueprint (Ad)
Poverty and inflation: Egypt's economy hit by global turmoil
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
The 3-Stock Retirement Blueprint (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Labour conference starts with focus on 'immoral' tax cuts
The 3-Stock Retirement Blueprint (Ad)
Poverty and inflation: Egypt's economy hit by global turmoil
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
The 3-Stock Retirement Blueprint (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Labour conference starts with focus on 'immoral' tax cuts
The 3-Stock Retirement Blueprint (Ad)
Poverty and inflation: Egypt's economy hit by global turmoil
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
The 3-Stock Retirement Blueprint (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Labour conference starts with focus on 'immoral' tax cuts
The 3-Stock Retirement Blueprint (Ad)
Poverty and inflation: Egypt's economy hit by global turmoil
Kim Kardashian culls Dolce & Gabbana archives for Milan show
NASDAQ:ADMS

Adamas Pharmaceuticals - ADMS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$8.22
$8.22
50-Day Range
$7.97
$8.23
52-Week Range
$4.02
$9.15
Volume
N/A
Average Volume
692,487 shs
Market Capitalization
$376.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.53
ADMS stock logo

About Adamas Pharmaceuticals (NASDAQ:ADMS) Stock

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Receive ADMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMS Stock News Headlines

Why Supernus' Acquisition of Adamas Is a Smart Move
See More Headlines

Receive ADMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMS Company Calendar

Last Earnings
11/11/2021
Today
9/25/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMS
Employees
138
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.53
High Stock Price Forecast
$9.10
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+3.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-57,400,000.00
Pretax Margin
-71.11%

Debt

Sales & Book Value

Annual Sales
$74.46 million
Book Value
($0.47) per share

Miscellaneous

Free Float
37,133,000
Market Cap
$376.37 million
Optionable
Optionable
Beta
2.82

Key Executives

  • Neil F. McFarlane
    Chief Executive Officer & Director
  • Christopher B. PrentissChristopher B. Prentiss
    Chief Financial Officer
  • Adrian Quartel
    Chief Medical Officer
  • Vijay ShreedharVijay Shreedhar
    Chief Commercial Officer
  • Jill M. Jene
    Head-Corporate Development & Strategy













ADMS Stock - Frequently Asked Questions

Should I buy or sell Adamas Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMS, but not buy additional shares or sell existing shares.
View ADMS analyst ratings
or view top-rated stocks.

What is Adamas Pharmaceuticals' stock price forecast for 2022?

6 brokers have issued 12 month price objectives for Adamas Pharmaceuticals' shares. Their ADMS share price forecasts range from $8.00 to $9.10. On average, they anticipate the company's share price to reach $8.53 in the next year. This suggests a possible upside of 3.8% from the stock's current price.
View analysts price targets for ADMS
or view top-rated stocks among Wall Street analysts.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) issued its quarterly earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to analysts' expectations of $25.07 million.

What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals Chief Executive Officer Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among the company's employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $8.22.

How much money does Adamas Pharmaceuticals make?

Adamas Pharmaceuticals (NASDAQ:ADMS) has a market capitalization of $376.37 million and generates $74.46 million in revenue each year. The specialty pharmaceutical company earns $-57,400,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

How many employees does Adamas Pharmaceuticals have?

The company employs 138 workers across the globe.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The official website for the company is www.adamaspharma.com. The specialty pharmaceutical company can be reached via phone at (510) 450-3500, via email at ir@adamaspharma.com, or via fax at 510-428-0519.

This page (NASDAQ:ADMS) was last updated on 9/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.